Polar Asset Management Partners’s BridgeBio Pharma BBIO Stock Holding History

Polar Asset Management Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,100	Closed	-$393K	–	686
2025 Q2	$393K	Buy	+9,100	New	+$331K	0.01%	418
2025 Q1	–	Sell	-46,900	Closed	-$1.29M	–	559
2024 Q4	$1.29M	Sell	46,900 -3,600	-7%	-$93K	0.02%	406
2024 Q3	$1.29M	Buy	+50,500	New	+$1.33M	0.03%	387

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Polar Asset Management Partners's BBIO Position: Q3 2025 in Review

Polar Asset Management Partners sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 9,100 shares — an estimated $393K sold.

Polar Asset Management Partners first reported a position in BBIO in Q3 2024 and held it in 3 quarters. The position peaked at $1.29M in Q4 2024. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Polar Asset Management Partners reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
Polar Asset Management Partners sold 9,100 BridgeBio Pharma shares in Q3 2025, an estimated $393K.
Polar Asset Management Partners first reported a position in BridgeBio Pharma in Q3 2024 and held it in 3 quarters.
Polar Asset Management Partners's BridgeBio Pharma position peaked at $1.29M in Q4 2024.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Polar Asset Management Partners's 13F filing for Q3 2025, filed 14 Nov 2025.